HU-LUYE@EC2612A

LEOCH INT'L

STARGLORY HLDGS

INTELLIMARK W27

BEST FOOD HLDG

GAOYU FINANCE

EXTREME VISION

TIAN TU CAPITAL

HSC RESOURCES

EPI (HOLDINGS)

LAP KEI ENGRG

06636

02650

00568

09973

03625

00175

02186

02333

00290

02315

EXTREME VISION(06636) rose 20.12%, with a trading turnover 255.1 Million HKD, and a year-to-date rose 149.3%. ZHIDA TECH(02650) rose 16.75%, with a trading turnover 19.3 Million HKD, and a year-to-date fell 21.7%. SHANDONG MOLONG(00568) rose 16.37%, with a trading turnover 3.9 Billion HKD, and a year-to-date rose 191.5%.

Top Gainers & Losers

ZHIDA TECH

SHANDONG MOLONG

CHERY AUTO

FOURSEMI

GEELY AUTO

LUYE PHARMA

GWMOTOR

GOFINTECH QUANT

BIOCYTOGEN-B

Top 10 HK Stock Gainers (4.2)

05818

Luye Pharma Group Books 31% Profit Growth in 2025; Shares Up 3%

marketscreener

LUYE PHA B2807

LUYE PHARMA POFF

Luye Pharma Group Books 31% Profit Growth in 2025; Shares Up 3%

01530

LUYE PHARMA (2186.HK) has recently seen its stock price continue to decline, temporarily retracing to the previous low point area. The daily death cross signal is clear, and the short-term bearish atmosphere dominates the market. From a technical perspective, major indicators such as MACD and RSI are showing weakness, with the 5-day and 10-day moving averages continuing to decline, and the K-line combination leaning towards bearish, indicating ongoing market selling pressure. 

On the fundamental side, although LUYE PHARMA has launched some new drugs, the industry as a whole has entered a complex phase of stricter policy regulation, price reductions in medical insurance, and high R&D investments, which affects performance improvement in the short term due to various uncertainties. The overall performance of the pharmaceutical sector has seen a recent decline in participation enthusiasm, with major institutions preferring defensive industries or rotating into high-growth areas. 

In terms of sector linkage, the pharmaceutical sector is weak, with noticeable short-term capital outflows. LUYE PHARMA is constrained by the overall atmosphere, facing systemic adjustment pressure brought about by the industry's "collective bearish" sentiment. In the current sensitive range of the retracement phase, both institutions and short-term funds remain highly sensitive, with price fluctuations easily triggering sector resonance. 

For future trends, attention should be paid to whether the support at this low point is effective. If strong support is breached, short-term bearish signals may further strengthen; conversely, if funds provide support and lead to a reversal of indicators, there may be a technical rebound in the short term. Investors should strictly control risks, primarily adopting a wait-and-see approach when the bottom is unclear, and if making tentative layouts, set appropriate stop-loss levels

Technical Forecast

3SBIO

Early Morning Trend | LUYE PHARMA retraces to the stage low, can sector linkage change the weakness?

159837

520880

159992

159316

510660

520690

513700

Luye Pharma Group has announced a RMB285 million capital injection into its subsidiary, Nanjing Luye, through a structured deal involving Nanjing Xinan and Ningbo Cinda. This investment will leave Luye Pharma with a 70.01% stake in the subsidiary. The deal includes equity option agreements allowing Luye’s affiliate to buy out new investors' stakes. This transaction is classified as a deemed partial disposal under Hong Kong listing rules, highlighting Luye's flexible financing strategy while maintaining control over its Nanjing operations. The current analyst rating for Luye Pharma stock is a Hold with a price target of HK$3.00.

Tip Ranks

E Fund CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Bosera Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

Luye Pharma Injects RMB285 Million into Nanjing Unit via Structured Deal

603368

Reuters

GUANGXI LIUYAO GROUP

Luye Pharma Completes Transfer of 25% Stake in Nanjing Luye to NJ Xinshi

560600

512010

512290

06955

513120

159892

513060

159506

159102

Founder Fubon CSI Medicine and Medical Device Innovation ETF

E Fund CSI 300 Health Care ETF

Guotai CSI Bio-medicine ETF

Tianhong CNI BIOMEDICINE ETF

BOAN BIOTECH

China Southern Hang Seng Biotech ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Penghua SSE STAR Biology and Medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

China Merchants CSI Biotechnology Theme ETF

Bosera Hang Seng Health Care ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Huaan Hang Seng Biotech ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

Yinhua CSI Research Sector 100 ETF

Shandong Boan Biotechnology Transfers 11.99 Million H Shares to Complete Minority Stake Deal

Shandong Boan Biotechnology Transfers 38.5 Million H Shares to New Investor

BOAN BIOTECH announced that its controlling shareholder LUYE PHARMA plans to arrange for its wholly-owned subsidiary Shandong Luye Pharma to further transfer 38.5 million H shares in the market on Thursday (22nd) as part of the proposed transfer. In December last year, LUYE PHARMA's wholly-owned subsidiary Luye Geneora issued several exchangeable preferred shares, allowing preferred shareholders to exchange the relevant shares for the existing H shares held by LUYE PHARMA, involving 100.5 million shares

AASTOCKS

BOAN BIOTECH's controlling shareholder plans to further transfer 38.5 million shares

China Accepts Luye Pharma's NDA for Ruoxinlin in Generalized Anxiety Disorder

HU-LUYE@EC2612A(27425.HK)

HU-LUYE@EC2612A Stock Performance Chart

Top 10 HK Stock Gainers (4.2)

Luye Pharma Group Books 31% Profit Growth in 2025; Shares Up 3%

Early Morning Trend | LUYE PHARMA retraces to the stage low, can sector linkage change the weakness?

Luye Pharma Injects RMB285 Million into Nanjing Unit via Structured Deal

Luye Pharma Completes Transfer of 25% Stake in Nanjing Luye to NJ Xinshi